Ersoy, AlparslanKoca, Nizameddin2026-04-092012-06Experimental and Clinical Transplantation, Cilt, 10, Sayı, 3, 2012 ss. 296-2981304-0855https://hdl.handle.net/11727/14860The mammalian target of rapamycin inhibitors is commonly preferred for solid organs for trans­plantation. Although these drugs have various adverse effects, sirolimus-related lymphedema has been rarely reported. We report a case of lymphedema related to everolimus after a kidney transplant. A 60-year-old woman successfully received a deceased-donor kidney. Everolimus was added to the treatment in postoperative month 3 owing to other immunosuppressive drugs’ adverse effects. Edema occurred first on her feet in the first year after the transplant. During 3 months’ follow-up, with no immunosuppressive adjustment, the edema progressed. Diagnosis of lymphedema was established. Several weeks after discontinuing everolimus, the patient’s lymphedema began to resolve itself and completely disappeared in 3 months. The mammalian target of rapamycin inhibitors rarely causes lymphedema by inhibiting different subtypes of vascular endothelial growth factors, which results in impaired lymphangiogenesis. While there are few reports about sirolimus-related lymphedema, this case represents the first everolimus-related case of lymphedema. Further studies are warranted to explain the underlying mechanisms.enEdemaImmunosuppressionKidney transplantmTOR inhibitorsComplicationCase Report1032146-8427